Search results
Showing 7851 to 7900 of 8236 results
We have moved Medical technologies guidance 41 to become HealthTech guidance 498. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PICO negative pressure wound dressings for closed surgical incisions (MTG43)
We have moved Medical technologies guidance 43 to become HealthTech guidance 509. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Medical technologies guidance 47 to become HealthTech guidance 538. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Medical technologies guidance 51 to become HealthTech guidance 556. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Medical technologies guidance 48 to become HealthTech guidance 543. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Axonics sacral neuromodulation system for treating refractory overactive bladder (MTG50)
We have moved Medical technologies guidance 50 to become HealthTech guidance 554. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Discontinued Reference number: GID-PHG59
We have moved Medical technologies guidance 62 to become HealthTech guidance 602. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
This advice has been updated and replaced by NICE healthtech guidance 562.
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development Reference number: GID-TA10858 Expected publication date: TBC
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
myCOPD for managing chronic obstructive pulmonary disease (MTG68)
This guidance has been updated and replaced by NICE healthtech guidance 736, which covers using myCOPD for self-management of chronic obstructure pulmonary disease (COPD), and NICE healthtech guidance 718, which covers using myCOPD for pulmonary rehabilitation.
Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)
This guidance has been updated and replaced by NICE interventional procedures guidance 807, 808 and 810.
Artificial intelligence for analysing chest X-ray images (MIB292)
This medtech innovation briefing has been updated and replaced by HealthTech guidance 696.
Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)
This advice has been updated and replaced by NICE healthtech guidance 736.
Space from Depression for treating adults with depression (MIB215)
This advice has been updated and replaced by NICE HealthTech guidance 675.
Discontinued Reference number: GID-TA11008
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.
In development Reference number: GID-TA11214 Expected publication date: TBC
In development Reference number: GID-TA11457 Expected publication date: TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
This guidance has been updated and replaced by NICE technology appraisal guidance 1119.
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
This guidance has been updated and replaced by NICE technology appraisal guidance 1120.
Discontinued Reference number: GID-TA10452
Discontinued Reference number: GID-TA11338
In development Reference number: GID-TA11365 Expected publication date: TBC
In development Reference number: GID-TA11709 Expected publication date: TBC
In development Reference number: GID-TA11689 Expected publication date: TBC
In development Reference number: GID-TA11679 Expected publication date: TBC
In development Reference number: GID-TA11631 Expected publication date: TBC
In development Reference number: GID-TA11523 Expected publication date: TBC
In development Reference number: GID-TA11455 Expected publication date: TBC
Discontinued Reference number: GID-TA11124
In development Reference number: GID-TA10826 Expected publication date: TBC
In development Reference number: GID-TA11352 Expected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development Reference number: GID-TA10779 Expected publication date: TBC
In development Reference number: GID-TA11645 Expected publication date: TBC
In development Reference number: GID-TA11589 Expected publication date: TBC
In development Reference number: GID-TA11586 Expected publication date: TBC
In development Reference number: GID-TA11299 Expected publication date: TBC
In development Reference number: GID-TA11406 Expected publication date: TBC
Discontinued Reference number: GID-TAG381
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Discontinued Reference number: GID-TA11411
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
Discontinued Reference number: GID-MT517
This guidance has been replaced by NICE guideline NG17.